SCHEMBL30041007

SCHEMBL30041007

C[C@@H](O)CNc1nnc(-c2ccc(C(F)(F)F)cc2C(F)(F)F)cc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 1/20 0.48
TRPV3 Q8NET8 2/20 0.40
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
CYP2C19 P33261 1/20 0.39
EIF4E P06730 1/20 0.38
CFTR P13569 1/20 0.38
CES2 O00748 1/20 0.36
PSMB11 A5LHX3 2/20 0.36
PSMA7 O14818 2/20 0.36
PSMB1 P20618 2/20 0.36
PSMA1 P25786 2/20 0.36
PSMA2 P25787 2/20 0.36
PSMA3 P25788 2/20 0.36
PSMA4 P25789 2/20 0.36
PSMB8 P28062 2/20 0.36
PSMB9 P28065 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32682445 0.87 NLRP3 (0.47) NLRP3TRPV3KDM4EALDH1A1HPGD
SCHEMBL30042431 0.84 NLRP3 (0.54) NLRP3TRPV3CFTRALOX5APFEN1
SCHEMBL30129718 0.84 NLRP3 (0.42) NLRP3TRPV3ALOX5APFEN1
SCHEMBL30041215 0.80 NLRP3 (0.48) NLRP3TRPV3KDM4EALDH1A1CFTR
Hydrochloric Acid SCHEMBL32682444 0.79 NLRP3 (0.47) NLRP3TRPV3KDM4EALDH1A1CFTR
SCHEMBL30042437 0.77 NLRP3 (0.45) NLRP3TRPV3KDM4EALDH1A1HSD17B10
SCHEMBL30129591 0.76 NLRP3 (0.44) NLRP3TRPV3KDM4EALDH1A1HPGD
SCHEMBL30042640 0.76 NLRP3 (0.62) NLRP3TRPV3CFTRBRAFKDR
SCHEMBL30041472 0.74 NLRP3 (0.64) NLRP3
SCHEMBL30041003 0.69 NLRP3 (0.49) NLRP3TRPV3BRAFKDRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4129986-B1 SUBSTITUTED PYRIDAZINE COMPOUND TENVIE THERAPEUTICS INC (US) 2026-03-11 EP disclosed
US-20230107277-A1 SUBSTITUTED PYRIDAZINE COMPOUND NICO THERAPEUTICS, INC. 2023-04-06 US disclosed
EP-4129986-A1 SUBSTITUTED PYRIDAZINE COMPOUND Astellas Pharma Inc. (JP) 2023-02-08 EP disclosed
CN-115279739-A Substituted pyridazine compounds 安斯泰来制药株式会社 2022-11-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230107277-A1 SUBSTITUTED PYRIDAZINE COMPOUND NLRP3, NLRP1, PYCARD NLRP3 1/4885TRPV3 406/4885KDM4E 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.